论文部分内容阅读
“齐二药”假药事件风波未平,紧接着又发生安徽华源“欣弗(通用名为克林霉素)”事件,目前,公众、媒体对药品安全性的关注达到前所未有的程度。针对“欣弗”引发的社会关注,本文就克林霉素的不良反应采访了有关药学专家。2003年国家药品不良反应监测中心曾发布有关克林霉素的不良反应信息,以提醒医生严格掌握克林霉素的适应症。专家建议:“是药三分毒”,任何人在使用药物治疗疾病的同时,都可能面对其引发不良反应的风险,克林霉素也是如此。临床使用要权衡利弊,严格按照说明书使用药物,同时要密切观察病人,一旦出现不良症状应及时救治。
At the same time, Anhui Huayuan “Xin Fu (commonly known as clindamycin)” incident occurred. At present, the public and the media are paying more attention to the safety of pharmaceutical products than ever before. In response to the social concern caused by “Xin Fu”, this article interviewed relevant pharmacologists on the adverse reactions of clindamycin. In 2003, the National Adverse Drug Reaction Monitoring Center released information on adverse reactions to clindamycin to remind doctors to strictly master the indications of clindamycin. Experts suggest that “it is a one-third drug”. Anyone using the drug to treat the disease may face the risk of adverse reactions. Clindamycin also does so. Clinical use to weigh the pros and cons, in strict accordance with the instructions of the use of drugs, while close observation of patients, in the event of adverse symptoms should be timely treatment.